References
- Ise T, Kreitman RJ, Pastan I, Nagata S. Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clin Chem Lab Med 2006;44:594–602.
- Matsushita K, Margulies I, Onda M, Soluble CD22 as a tumor marker for hairy cell leukemia. Blood 2008;112:2272–2277.
- Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990;113:619–627.
- Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol 2004;173:5343–5348.
- Junghans RP, Waldmann TA. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 1996;183:1587–1602.
- Sheu BC, Hsu SM, Ho HN, A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001;61:237–242.
- Chilosi M, Semenzato G, Cetto G, Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987;70:1530–1535.
- Steis RG, Marcon L, Clark J, Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988;71:1304–1309.
- Smith JW, Longo DL, Urba WJ, Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Blood 1991;78:1664–1671.
- Arun B, Curti BD, Longo DL, Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am 2000;6:21–24.